Tectonic Therapeutic, Inc. TECX R2KR3KPHARMA
Company Overview
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -9.14% |
| 6 Months: | -29.68% |
| 3 Months: | -34.43% |
| 1 Month: | -16.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross2d ago
- RSI (14)29.42 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 47.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TECX Tectonic Therapeutic, Inc. R2KR3KPHARMA | 20.07 | -4.39 | $392.36M | 0.00% | -33.43% | -33.80% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.54M | -6.37M | -7.79M | -9.55M | -12.23M | -17.70M | -16.61M | -18.06M | -26.59M | -28.86M | -36.72M | -26.88M | -31.38M | -32.62M | -29.42M | -27.77M | -22.98M | -25.22M | -10.63M | -10.11M | -12.97M | -11.42M | -19.64M | -18.30M | -22.33M | -21.89M | -27.30M | -24.22M |
| Net Income | -2.53M | -6.44M | -8.24M | -10.51M | -11.59M | -17.10M | -16.05M | -17.14M | -25.97M | -28.83M | -36.78M | -26.90M | -31.39M | -32.61M | -29.83M | -28.05M | -22.97M | -14.45M | -10.46M | -10.05M | -15.22M | -12.67M | -17.72M | -15.91M | -19.98M | -19.04M | -25.24M | -22.29M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.74 | -0.75 | -0.68 | -0.64 | -0.52 | -0.57 | -8.51 | -7.62 | -10.97 | -4.34 | -1.20 | -0.93 | -1.07 | -1.02 | -1.34 | -1.18 |
| R&D Expense | 1.88M | 5.41M | 5.65M | 7.41M | 9.23M | 12.45M | 12.27M | 13.04M | 18.27M | 20.87M | 28.51M | 18.53M | 22.54M | 23.04M | 19.25M | 18.88M | 15.92M | 17.33M | 8.77M | 8.13M | 10.82M | 7.07M | 14.32M | 13.04M | 17.18M | 16.93M | 20.87M | 18.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -18.39M | -46.24M | -75.81M | -120.23M | -118.84M | -105.43M | -44.65M | -58.02M | -84.04M |
| Net Income | -18.65M | -46.36M | -72.97M | -119.71M | -119.13M | -105.89M | -42.82M | -57.98M | -74.15M |
| Diluted EPS | - | - | - | - | -2.78 | -2.42 | -33.76 | -6.83 | -4.05 |
| R&D Expense | 15.19M | 35.09M | 54.97M | 87.24M | 83.11M | 72.19M | 36.97M | 41.36M | 63.49M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.02M | 133.48M | 200.51M | 271.23M | 203.84M | 103.95M | 39.40M | 152.91M | 261.04M |
| Total Equity | -4.58M | -23.14M | 122.18M | 186.01M | 254.34M | 169.48M | -45.65M | -84.64M | 140.78M | 251.33M |
| Cash & Equivalents | - | 5.96M | 126.30M | 187.04M | 259.68M | 189.57M | 92.56M | 28.77M | 141.24M | 253.80M |
| Long Term Debt | - | - | - | - | - | 15.00M | 15.00M | - | - | - |
| Total Liabilities | - | 3.66M | 11.29M | 14.50M | 16.89M | 34.36M | 28.58M | 43.41M | 12.13M | 9.71M |
| Current Liabilities | - | 2.62M | 10.61M | 14.02M | 16.61M | 19.39M | 13.12M | 40.89M | 11.61M | 9.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.38M | -37.65M | -67.67M | -98.80M | -98.03M | -97.21M | -40.68M | -59.08M | -60.08M |
| Investing Cash Flow | -383.00K | -1.83M | -1.58M | -1.18M | -2.46M | -267.00K | -279.00K | -156.00K | -138.00K |
| Financing Cash Flow | 17.37M | 160.29M | 129.99M | 172.62M | 30.37M | 262.00K | 33.75M | 171.71M | 173.35M |
| Capital Expenditure | -383.00K | -1.83M | -1.58M | -1.18M | -2.46M | -267.00K | -279.00K | -156.00K | -208.00K |
| Free Cash Flow | -16.77M | -39.48M | -69.25M | -99.98M | -100.49M | -97.47M | -40.96M | -59.24M | -60.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| ROE % | 80.6% | -37.9% | -39.2% | -47.1% | -70.3% | 231.9% | 50.6% | -41.2% | -29.5% |
| ROCE % | -418.1% | -37.6% | -40.6% | -47.2% | -64.4% | -116.1% | 2,998.5% | -41.1% | -33.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.48% | 2.83M | $66.03M |
| 2 | TCG Crossover Management, LLC | 6.16% | 1.20M | $28.11M |
| 3 | Aberdeen Group plc | 5.84% | 1.14M | $26.64M |
| 4 | Blackrock Inc. | 4.41% | 862.59K | $20.12M |
| 5 | First Light Asset Management, LLC | 4.10% | 800.73K | $18.68M |
| 6 | Baker Bros. Advisors, LP | 3.11% | 607.79K | $14.18M |
| 7 | 5AM Venture Management, LLC | 3.10% | 606.66K | $14.15M |
| 8 | Braidwell LP | 3.05% | 596.90K | $13.93M |
| 9 | Vanguard Capital Management LLC | 2.50% | 488.81K | $11.40M |
| 10 | Vestal Point Capital, LP | 2.17% | 425.00K | $9.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TECX
TECX: Tectonic Therapeutic Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE9Zd3ZWZVpnX0lvZDNmUkp6ellJWUs3SWlxVEhkdWNsS1k2UUZRTC1MNW5rbENRUFlLSWkzVWEwR25peFdZYXgwMXpn?oc=5" target="_blank">TECX: Tectonic Therapeutic Inc. Latest Stock Price, Analysis, News …
TECX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1nUkxCQ3ZCZU9Gdzg0b0NsX3cyUmF1ZDd0ZkE1VFpkZ0pVY0xNYkh6VnkyR2xEZUxyeDY5ZGJFZlZfWmRDV3pLN2FvTlJEQU9tM09lU0M0Y3hscTFJbEZLZmxCcFFNQ2t1cXh1TVV3bjVEVkoydHN0MnB3?oc=5" target="_blank">TEC…
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNb3pHRTdYUGlwNk84VkxZZ2Zpb2ptWVRRMHBFTm1mUmxMWVFYU2J0NlRtSVJMOThFbW5pNXFFUmh1NjJHak1NNjRNWjBSVHIxWWYzakVkdU5TMUFJbElDaHhOUmc3NkRNRFdrU3lCWHdVQmJkZ09RNFp3R0M5VGxxb2VvbHlENHptQWZtTE…
(TECX) Technical Patterns and Signals (TECX:CA) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQWUw5UHEzMm9WblBZS09HODVDUGQtZlBxNkxBc0FNVGVmeFBPVC1BRnA0S0l5d3Nwd1RrZXV2bGR5U0RxTlBSVVZmUEtYWjRITUh0T0lsWEttNjlCLXh0NGQwSTEwLU8zZnpWTEhfekV1UTFSUW9kZnJnb1F2RkhQWHdBRmM0NDVXUVdNRH…
$TECX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOc0lmUGxmYmU5NnU4NEZZcXFMM0F4dWdqTTU0cGstSmFKakhkSmVQVmU1b1NTSTFkWC1mS2k1TnAySlhsMWx4bHpGdkNhM3R6UUs3WWJSb2V2cjBFYy1OT3I0dENXLXJ2MEtpMGt2bTlvOEpwMXctbGwwaWNVWmlPM3R1YnhPY0ZpUXJLdW…
TECX CVR: TECX^ Stock Price Quote & News - Robinhood
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE0xc0RBUmJ4cjBQblBSYnh2SmhIODBiTWZEX3BzUEhfZEFDbEtwX0ZEdzZjeHN1VnU4M056VEZoWE0wQUUxQWs0bEV6SFQ3VEZFVEFUR2ln?oc=5" target="_blank">TECX CVR: TECX^ Stock Price Quote & News</a> &…
TECX — Frequently Asked Questions
What is the current share price of Tectonic Therapeutic, Inc. (TECX)?
As of 2026-10-23 16:27 PDT, Tectonic Therapeutic, Inc. (TECX) trades at $20.07 on NasdaqGM. Its 52-week range is $14.71 to $37.93.
What is the market capitalisation of TECX?
Tectonic Therapeutic, Inc. (TECX) has a market capitalisation of $392.36M on NasdaqGM.
What is the P/E ratio of TECX?
TECX trades at a trailing price-to-earnings (P/E) ratio of -4.39. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.21.
What is the return on equity (ROE) of TECX?
TECX has a return on equity (ROE) of -33.80%. Its return on capital employed (ROCE) is -33.43%.
Is TECX a good stock to buy?
This page provides a data-driven analysis of Tectonic Therapeutic, Inc. (TECX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.